[Diethylstilbestrol intervention in carcinogenesis of breast cancer in wistar rats].
As a synthesized estrogenic drug, diethylstilbestrol (DES) is generally used to cure diseases like climacteric period syndrome and osteoporosis due to estrogen insufficient, but its effect on mammary gland epithelial cells is still unclear. This study was to observe the effect of DES on dimethylbenzanthracene (DMBA)-induced carcinogenesis of breast cancer in Wistar rats. A total of 90 Wistar rats were equally divided into control, DES(1), DMBA, DES(1) plus DMBA, DES(2) plus DMBA, and DES(3) plus DMBA groups. The rats were perfused with DMBA at a dose of 100 mg/kg on Days 1 and 30, and DES at a dose of 0.1 mg x kg(-1) x d(-1) (DES(1)), 0.2 mg x kg(-1) x d(-1) (DES(2)), or 0.4 mg x kg(-1) x d(-1) (DES(3)), respectively. All rats were killed after 44 weeks. The morphology of the breast tissue was observed; silver-binding nucleolar organizer regions (AgNOR) were counted; proliferating cell nuclear antigen (PCNA) staining intensity index (SII), the protein expression of Bcl-2, and C-erbB-2 were detected by SP immunohistochemistry. Among 15 rats with breast cancer carcinogenesis, 2 came from DES(1) plus DMBA group and 13 from DMBA group. AgNOR count, and the levels of PCNA SII, Bcl-2, and C-erbB-2 were higher in DES(1) group than in control group; AgNOR count, and the levels of PCNA SII, Bcl-2, and C-erbB-2 were significantly lower in DES(2) plus DMBA group than in DES(3) plus DMBA group and DES(1) plus DMBA group (P < 0.05), but there was no significant difference between DES(3) plus DMBA group and DES(1) plus DMBA group (P > 0.05). Low dose of DES can cause hyperplasia of the mammary gland in Wistar rats but not lead to carcinogenesis. During the DMBA-induced carcinogenesis of breast cancer in Wistar rats, low dose of DES can promote the hyperplasia and carcinogenesis of the mammary gland, medium dose of DES can inhibit the proliferation of mammary epithelial cells, but the effect may weaken while increasing the dose of DES.